Risk factors for local recurrence after breast-conserving therapy for invasive carcinomas: A case-control study of histological factors and alterations in oncogene expression

Elkhuizen, Paula H.M.; Voogd, A.C.; Broek, L.C.J.M. van den; Tan, Ting; Houwelingen, Hans C. van; Leer, J.W.H.; Vijver, Marc J. van de

doi:10.1016/s0959-8049(98)80393-6

Cited by 13 publications

(23 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a pilot case-control study of conservatively managed breast cancer patients, Haffty et al (1996) observed that patients who sustained a local relapse were more likely to overexpress HER-2/Neu. A similar trend was noted in conservatively treated patients in a study by Elkhuizen et al (1999), although the difference did not reach statistical significance. More recently, in a cohort of patients treated with radiation for postmastectomy chest wall relapses, we have observed a higher rate of chest wall progression in patients overexpressing HER-2/neu (Pentopoulos et al, 2002).…”

Section: Her-2/neusupporting

confidence: 70%

“…In a case control study of locally recurrent breast cancer patients and a matched group of locally controlled patients, Turner et al (2000a) observed a higher rate of overexpression of P53 in the locally recurrent cohort. A similar study reported by Elkhuizen et al (1999), however, failed to show a correlation between P53 expression and local control in conservatively managed breast cancer patients. Silvestrini et al (1997b) also did not show a correlation with local relapse following conservative surgery and radiation.…”

Section: P53supporting

confidence: 49%

“…Patients with metastatic disease who overexpress HER-2/neu benefit significantly from antibody therapy alone or antibody to HER-2/neu in combination with cytoxic chemotherapy (Slamon, 1999). Data regarding HER-2/neu and radiation sensitivity are less prevalent, but there appears to be both laboratory and clinical data suggesting that patients who overexpress HER-2/neu do not respond as well as others (Pietras et al, 1994;Haffty et al, 1996;Stackhouse et al, 1998;Elkhuizen et al, 1999;Pietras et al, 1999;Rao et al, 2000;Uno et al, 2001;Wang and Hung, 2001;Contessa et al, 2002;Formenti et al, 2002;Pentopoulos et al, 2002).…”

Section: Her-2/neumentioning

confidence: 99%

“…Given the complexities noted above, along with heterogeneity between and within the clinical data sets evaluated, the studies to date have been inconsistent and conflicting (Caminero et al, 1996;Koch et al, 1996;Silvestrini et al, 1997b;Wood et al, 1997;Gasparini et al, 1998;Mineta et al, 1998;Nogueira et al, 1998;Pai et al, 1998;Bradford, 1999;Elkhuizen et al, 1999;Unal et al, 1999;Cabelguenne et al, 2000;Dijkema et al, 2000;Elsaleh et al, 2000;Linderholm et al, 2000b;Narayana et al, 2000;Obata et al, 2000;Overgaard et al, 2000;Shintani et al, 2000;Turner et al, 2000a;Zellars et al, 2000;Alsner et al, 2001;Edstrom et al, 2001;Koelbl et al, 2001;Ritter et al, 2002). There have been, however, numerous studies suggesting that P53 may be a significant factor in predicting response to radiation.…”

Section: P53mentioning

confidence: 99%

“…There have been numerous studies in other sites, including cervix, lung, prostate, colorectal and brain, which demonstrate both positive and negative results using P53 expression as a prognostic factor for radiation sensitivity and local control with therapeutic doses of radiation (Caminero et al, 1996;Koch et al, 1996;Silvestrini et al, 1997b;Wood et al, 1997;Gasparini et al, 1998;Mineta et al, 1998;Nogueira et al, 1998;Pai et al, 1998;Bradford, 1999;Elkhuizen et al, 1999;Unal et al, 1999;Cabelguenne et Koelbl et al, 2001;Ritter et al, 2002). It is apparent that the data with respect to P53 overexpression, based on immuno-histochemical staining, remains conflicting.…”

Section: P53mentioning

confidence: 99%

See 4 more Smart Citations

Molecular markers in clinical radiation oncology

Haffty¹,

Glazer²

2003

Oncogene

View full text Add to dashboard Cite

Radiation therapy plays a critical role in the management of a majority of patients diagnosed with cancer. Identification of factors that help predict which patients are at risk for relapse within the irradiated field remains an active area of investigation. Although conventional clinical and pathologic factors have been helpful in identifying risk and guiding clinical decision-making for both local and systemic management, there is clearly a need to identify additional prognostic markers, which can aid in refining our treatment strategies and improving outcomes. A substantial amount of research efforts have been devoted to identifying molecular markers for prognostic and therapeutic strategies. The recent emergence of a powerful armamentarium of molecular tools has resulted in rapid expansion of our fund of knowledge and understanding of the molecular biology underlying tumor behavior and response. While a majority of these efforts have been focused on risk factors for metastatic disease and survival, there is a rapidly growing body of literature focused on molecular factors associated with radiation resistance and locoregional failure. In this review, we summarize recent advances and the available literature evaluating molecular markers as they relate to radiation sensitivity of solid tumors. Literature regarding the potential application of expression of genes related to apoptosis, angiogenesis, cell cycle, DNA repair and growth factors will be reviewed. Some of the basic biology and laboratory evidence demonstrating how the marker relates to radiation response and available correlative clinical studies employing these markers as prognostic tools are presented. The majority of molecular markers that have potential clinical significance with respect to radiation sensitivity and local control will be highlighted.

show abstract

Section: Her-2/neusupporting

confidence: 70%

Section: P53supporting

confidence: 49%

Section: Her-2/neumentioning

confidence: 99%

Section: P53mentioning

confidence: 99%

Section: P53mentioning

confidence: 99%

See 3 more Smart Citations

Molecular markers in clinical radiation oncology

Haffty¹,

Glazer²

2003

Oncogene

View full text Add to dashboard Cite

show abstract

Effect of breast‐conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma

Kroman

Holtveg²,

Wohlfahrt

et al. 2004

Cancer

136

View full text Add to dashboard Cite

show abstract

The use of Bcl-2 and PTHLH immunohistochemistry in the diagnosis of peripheral chondrosarcoma in a clinicopathological setting

et al. 2005

View full text Add to dashboard Cite

Distinguishing osteochondroma from low-grade secondary peripheral chondrosarcoma can be difficult. In osteochondroma, growth-signalling pathways are thought to be downregulated through exostosin (EXT) inactivation. A previous pilot study focusing on expression of putative EXT downstream effectors indicated that progression of osteochondroma towards grade I chondrosarcoma was characterised by upregulation of Bcl-2 and parathyroid hormone-like hormone (PTHLH). We investigated their use as diagnostic markers in a large nationwide series of 71 osteochondromas and 34 chondrosarcomas. Bcl-2 immunohistochemistry proved to be a valuable diagnostic tool: scoring negative in 95% (specificity) of the osteochondromas and positive in 57% (sensitivity) of the chondrosarcomas, reaching a positive predictive value of 84% and negative predictive value of 82%. Positivity was not related to age, hereditary status, gender or thickness of the cartilage cap. Presence of internal controls and verification using mRNA in situ hybridisation strengthened the reliability of the immunohistochemical staining. PTHLH showed more variable staining, being positive in osteochondromas from females or adolescent males, suggesting age- and gender-dependent expression. Thus, in cases where the distinction between osteochondroma and chondrosarcoma is difficult, Bcl-2 is a valuable diagnostic marker for malignancy, regardless of tumour size, patient gender or age, and this can be extended with PTHLH for non-adolescent male patients.

show abstract

Risk factors for local recurrence after breast-conserving therapy for invasive carcinomas: A case-control study of histological factors and alterations in oncogene expression

Cited by 13 publications

References 0 publications

Molecular markers in clinical radiation oncology

Molecular markers in clinical radiation oncology

Effect of breast‐conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma

The use of Bcl-2 and PTHLH immunohistochemistry in the diagnosis of peripheral chondrosarcoma in a clinicopathological setting

Contact Info

Product

Resources

About